The objective of the study was to evaluate the degree of improvement in lung function in
patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium
inhalation capsules compared to salmeterol inhalation aerosol .
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
HEMO Oy Health Center, Lahti, Finland
Boehringer Ingelheim Investigational Site, Mikkeli, Finland
Boehringer Ingelheim Investigational Site, Oulu, Finland
Gen. Hosp. "Evangelismos",, Athens, Greece
Gen. Hosp. of Chest Diseases "Sotiria", Athens, Greece
Gen. Hosp. of Chest Diseases"Sotiria", Athens, Greece
University Hospital of Ioannina, Ioannina, Greece
General Hospital "Sismanoglio", 3rd Pneumonology Dpt, Maroussi, Athens, Greece
General Hospital "Papanicolaou",, Thessaloniki, Greece
Azienda Ospedaliera S. Martino, Genova, Italy
A.O. Pisana, Pisa, Italy
Hospital de Santa Maria, Lisboa, Portugal
Hospital Pulido Valente, Lisboa, Portugal
Hospital de São João, Porto, Portugal
Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal
Lindesbergs lasarett, Lindesberg, Sweden
Boehringer Ingelheim Investigational Site, Linköping, Sweden
Vårdcentralen Brinken, Motala, Sweden
Boehringer Ingelheim Investigational Site, Stockholm, Sweden
Fysiologlaboratoriet, Stockholm, Sweden
Boehringer Ingelheim Investigational Site, Uppsala, Sweden
Boehringer Ingelheim Investigational Site, Örebro, Sweden
Gazi Universitesi Tip Fakultesi, Ankara, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakültesi, Istanbul, Turkey
Yedikule Gögüs Hastaliklari Hastanesi, Istanbul, Turkey
Ege Universitesi Tip Fakultesi, Izmir, Turkey
Frenchay Healthcare NHS Trust, Bristol, United Kingdom
Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom
West Middlesex University Hospital, Isleworth, United Kingdom
Medicines Evaluation Unit, Manchester, United Kingdom
UAB Medical Center, Birmingham, Alabama, United States
Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States
Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States
Southern Arizona VA Health Care System, Tuscon, Arizona, United States
Boehringer Ingelheim Investigational Site, Fullerton, California, United States
VA Greater Los angeles Health Care Systems, Sepulveda, California, United States
Olive View UCLA Medical Center, Sylmar, California, United States
Boehringer Ingelheim Investigational Site, Boulder, Colorado, United States
Colorado Pulmonary Associates, Denver, Colorado, United States
Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States
Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
University Medical Associates, LLP, Augusta, Georgia, United States
Boehringer Ingelheim Investigational Site, Coeur d' Alene, Idaho, United States
LSU MC-Sheveport, Shreveport, Louisiana, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
The Oregon Clinic, Portland, Oregon, United States
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
Attention: Thomas D. Kaelin, Jr., D.O., Charleston, South Carolina, United States
Boehringer Ingelheim Investigational Site, Houston, Texas, United States